Treatment efficacy of a probiotic preparation for non‐alcoholic steatohepatitis: A pilot trial

Manzhalii, Elina; Virchenko, Oleksandr; Falalyeyeva, Tetyana; Beregova, Tetyana; Stremmel, Wolfgang

doi:10.1111/1751-2980.12561

Cited by 84 publications

(69 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…We identified 1934 records, from which we selected 986 individual abstracts and 161 potentially relevant articles for full review (figure 1). We identified 105 articles19 25–128 reporting data from 99 different research studies including 111 different randomised comparisons of probiotics versus control (further called randomised clinical trials [RCTs], see online supplementary table 1-2) with the following outcomes: BW (number of RCTs: k=58, n=3422 individuals, median=77.4 kg), BMI (k=68, n=4015, 28.2 kg/m²), WC (k=26, n=1583, 98.8 cm); BFM (k=27, n=1562, 27.8 kg), SAT and VAT (k=5, n=543, 192.4 cm² and 114.7 cm², respectively), FG (k=83, n=5188, 6.1 mmol), HbA 1c (k=28, n=1796, 6.3%), INS (k=63, n=3854, 11.0 mU/L), HOMA-IR (k=52, n=3513, 3.2), CRP (k=41, n=2376, 3.6 mg/L), TG (k=74, n=4461, 145.4 mg/dL), ALAT (k=26, n=1466, 38.6 IU/L), ASAT (k=23, n=1340, 36.1 IU/L) and GGT (k=14, n=816, 41.5 IU/L). The median duration of the follow-up was 8 weeks (range: 2–28 weeks), probiotics dose ranged from 10 7 to 10 12 CFU daily, and 43 trials were conducted in one country (Iran).…”

Section: Resultsmentioning

confidence: 99%

Impact of bacterial probiotics on obesity, diabetes and non-alcoholic fatty liver disease related variables: a systematic review and meta-analysis of randomised controlled trials

et al. 2019

View full text Add to dashboard Cite

ObjectiveTo systematically review the effect of oral intake of bacterial probiotics on 15 variables related to obesity, diabetes and non-alcoholic fatty liver disease.DesignSystematic review and meta-analysis.Data sourcesMedline, EMBASE and COCHRANE from 1990 to June 2018.Eligibility criteriaRandomised controlled trials (≥14 days) excluding hypercholesterolaemia, alcoholic liver disease, polycystic ovary syndrome and children <3 years.ResultsOne hundred and five articles met inclusion criteria, representing 6826 subjects. In overweight but not obese subjects, probiotics induced improvements in: body weight (k=25 trials, d=−0.94 kg mean difference, 95% CI −1.17 to −0.70, I²=0.0%), body mass index (k=32, d=−0.55 kg/m², 95% CI −0.86 to −0.23, I²=91.9%), waist circumference (k=13, d=−1.31 cm, 95% CI −1.79 to −0.83, I²=14.5%), body fat mass (k=11, d=−0.96 kg, 95% CI −1.21 to −0.71, I²=0.0%) and visceral adipose tissue mass (k=5, d=−6.30 cm², 95% CI −9.05 to −3.56, I²=0.0%). In type 2 diabetics, probiotics reduced fasting glucose (k=19, d=−0.66 mmol/L, 95% CI −1.00 to −0.31, I²=27.7%), glycated haemoglobin (k=13, d=−0.28 pp, 95% CI −0.46 to −0.11, I²=54.1%), insulin (k=13, d=−1.66 mU/L, 95% CI −2.70 to −0.61, I²=37.8%) and homeostatic model of insulin resistance (k=10, d=−1.05 pp, 95% CI −1.48 to −0.61, I²=18.2%). In subjects with fatty liver diseases, probiotics reduced alanine (k=12, d=−10.2 U/L, 95% CI −14.3 to −6.0, I²=93.50%) and aspartate aminotransferases (k=10, d=−9.9 U/L, 95% CI −14.1 to -5.8, I²=96.1%). These improvements were mostly observed with bifidobacteria (Bifidobacterium breve, B. longum), Streptococcus salivarius subsp. thermophilus and lactobacilli (Lactobacillus acidophilus, L. casei, L. delbrueckii) containing mixtures and influenced by trials conducted in one country.ConclusionsThe intake of probiotics resulted in minor but consistent improvements in several metabolic risk factors in subjects with metabolic diseases.Trial registration numberCRD42016033273.

show abstract

Section: Resultsmentioning

confidence: 99%

Impact of bacterial probiotics on obesity, diabetes and non-alcoholic fatty liver disease related variables: a systematic review and meta-analysis of randomised controlled trials

et al. 2019

View full text Add to dashboard Cite

show abstract

“…In this phase, liver fibrosis is irreversible due to development of collagen crosslinks; as a result, any beneficial effects of probiotics at this stage of fibrosis would be highly improbable. Hence, while recent investigations with numerous strains of probiotics, including Lactobacillus rhamnosus, Lactobacillus plantarum bulgaricus, and Lactobacillus casei showed positive effects in rodent models [134][135][136][137], randomized clinical trial data collected long-term are not presently available.…”

Section: Association Between Probiotics and Clinical Outcomes In Hepamentioning

confidence: 99%

Intestinally derived bacterial products stimulate development of nonalcoholic steatohepatitis

Dornas

Lagente

2019

Pharmacological Research

View full text Add to dashboard Cite

Fatty livers are susceptible to factors that cause inflammation and fibrosis, but fat deposition and the inflammatory response can be dissociated. While nonalcoholic fatty liver disease (NAFLD), caused by pathologic fat accumulation inside the liver, can remain stable for several years, in other cases NAFLD progresses to nonalcoholic steatohepatitis (NASH), which is characterized by fat accumulation and inflammation and is not a benign condition. In this review, we discuss the NASH host cells and microbial mechanisms that stimulate inflammation and predispose the liver to hepatocyte injury and fibrotic stages via increased lipid deposition. We highlight the interactions between intestine-derived bacterial products, such as lipopolysaccharide, and nutritional models of NAFLD and/or obese individuals. The results of modulating enteric microbiota suggest that gut-derived endotoxins may be essential determinants of fibrotic progression and regression in NASH.

show abstract

“…The continuous and recurrent course of hepatic and intestinal diseases is accompanied by a progressive structural and functional damage of these organs and is accompanied by a significant decrease in quality of life. This allows considering these diseases in terms of being both important medical and social problems and envisages the search for new directions of improving treatment and prevention of this pathology [1][2][3][4][5].…”

Section: Introductionmentioning

confidence: 99%

“…According to the literature, 37% of all patients with chronic colitis (CC) are diagnosed with fatty infiltration of the liver [6,7]. The course of hepatic and intestinal diseases is often accompanied by the damage to the intestinal microflora that contributes to the development of metabolic disorders and chronic intoxication [3]. Excessive accumulation of free radicals and lipid peroxidation products is one of the leading pathogenetic mechanisms of hepatocellular lesions due to the damage to the lipid layer of cell membranes and to metabolic disorders in the liver with the subsequent development of biliary insufficiency (BI) [8,9].…”

Section: Introductionmentioning

confidence: 99%

Increasing efficacy of treatment in patients with steatohepatitis and concomitant chronic colitis

Manzhalii

Moyseyenko

Falalyeyeva

et al. 2019

Current Issues in Pharmacy and Medical Sciences

View full text Add to dashboard Cite

This paper presents the results of a study of patients with nonalcoholic steatohepatitis, alcoholic steatohepatitis, and drug-induced liver injury with concomitant colitis and the development of biliary insufficiency that manifests as a significant decrease in the volume of bile acids and bile. In patients with liver injury and concomitant colitis, changes in intestinal microflora were marked. After a combination therapy of this pathology with phosphatidylcholine and glycyrrhizic acid, an improvement of biochemical, clinical indicators was observed, as well as a decrease in fatty degeneration and reduction of elastographic indicators of liver fibrosis. The introduction of the drug formulations phosphatidylcholine and glycyrrhizic acid in the complex of conservative treatment of liver injury with concomitant colitis helps to prevent hepatic and intestinal complications and to increase the treatment efficacy of these diseases.

show abstract

Treatment efficacy of a probiotic preparation for non‐alcoholic steatohepatitis: A pilot trial

Abstract: Short-term treatment with the probiotic cocktail caused significant improvement of liver inflammation without adverse events and, thus, may represent a promising candidate therapeutic approach for NASH.

Cited by 84 publications

References 16 publications

Impact of bacterial probiotics on obesity, diabetes and non-alcoholic fatty liver disease related variables: a systematic review and meta-analysis of randomised controlled trials

Impact of bacterial probiotics on obesity, diabetes and non-alcoholic fatty liver disease related variables: a systematic review and meta-analysis of randomised controlled trials

Intestinally derived bacterial products stimulate development of nonalcoholic steatohepatitis

Increasing efficacy of treatment in patients with steatohepatitis and concomitant chronic colitis

Contact Info

Product

Resources

About